Excelsior Biopharma Past Earnings Performance
Past criteria checks 0/6
Excelsior Biopharma's earnings have been declining at an average annual rate of -75.4%, while the Healthcare industry saw earnings growing at 6.8% annually. Revenues have been declining at an average rate of 18.5% per year.
Key information
-75.4%
Earnings growth rate
-75.4%
EPS growth rate
| Healthcare Industry Growth | 9.1% |
| Revenue growth rate | -18.5% |
| Return on equity | -8.2% |
| Net Margin | -10.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Be Wary Of Excelsior Biopharma (GTSM:6496) And Its Returns On Capital
Apr 01
Is Excelsior Biopharma Inc. (GTSM:6496) An Attractive Dividend Stock?
Mar 11Is Excelsior Biopharma (GTSM:6496) Using Too Much Debt?
Feb 09Are Poor Financial Prospects Dragging Down Excelsior Biopharma Inc. (GTSM:6496 Stock?
Jan 11
Our Take On The Returns On Capital At Excelsior Biopharma (GTSM:6496)
Dec 22Here's Why Excelsior Biopharma's (GTSM:6496) Statutory Earnings Are Arguably Too Conservative
Nov 30Revenue & Expenses Breakdown
How Excelsior Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 799 | -86 | 354 | 75 |
| 31 Mar 24 | 774 | -101 | 341 | 71 |
| 31 Dec 23 | 772 | -91 | 326 | 63 |
| 30 Sep 23 | 730 | -98 | 309 | 55 |
| 30 Jun 23 | 719 | -71 | 299 | 42 |
| 31 Mar 23 | 686 | -48 | 277 | 43 |
| 31 Dec 22 | 672 | -34 | 274 | 42 |
| 30 Sep 22 | 872 | -35 | 281 | 54 |
| 30 Jun 22 | 997 | -38 | 267 | 60 |
| 31 Mar 22 | 1,167 | -28 | 263 | 52 |
| 31 Dec 21 | 1,338 | -16 | 246 | 56 |
| 30 Sep 21 | 1,315 | -9 | 230 | 53 |
| 30 Jun 21 | 1,382 | 12 | 218 | 53 |
| 31 Mar 21 | 1,443 | 25 | 209 | 61 |
| 31 Dec 20 | 1,444 | 35 | 211 | 57 |
| 30 Sep 20 | 1,524 | 55 | 213 | 62 |
| 30 Jun 20 | 1,518 | 62 | 208 | 59 |
| 31 Mar 20 | 1,517 | 68 | 214 | 52 |
| 31 Dec 19 | 1,540 | 71 | 216 | 51 |
| 30 Sep 19 | 1,538 | 106 | 222 | 42 |
| 30 Jun 19 | 1,594 | 148 | 239 | 41 |
| 31 Mar 19 | 1,641 | 174 | 257 | 43 |
| 31 Dec 18 | 1,689 | 222 | 264 | 39 |
| 30 Sep 18 | 1,689 | 230 | 272 | 58 |
| 30 Jun 18 | 1,711 | 249 | 280 | 58 |
| 31 Mar 18 | 1,696 | 281 | 273 | 55 |
| 31 Dec 17 | 1,716 | 280 | 282 | 60 |
| 30 Sep 17 | 1,719 | 269 | 278 | 61 |
| 30 Jun 17 | 1,702 | 262 | 276 | 63 |
| 31 Mar 17 | 1,628 | 220 | 280 | 64 |
| 31 Dec 16 | 1,535 | 180 | 270 | 66 |
| 30 Sep 16 | 1,425 | 162 | 266 | 46 |
| 30 Jun 16 | 1,312 | 128 | 254 | 42 |
| 31 Mar 16 | 1,281 | 131 | 236 | 39 |
| 31 Dec 15 | 1,238 | 143 | 228 | 34 |
| 30 Sep 15 | 1,216 | 143 | 208 | 38 |
| 30 Jun 15 | 1,210 | 153 | 208 | 50 |
| 31 Mar 15 | 1,180 | 158 | 216 | 60 |
| 31 Dec 14 | 1,147 | 154 | 202 | 71 |
| 31 Dec 13 | 954 | 157 | 269 | 12 |
Quality Earnings: 6496 is currently unprofitable.
Growing Profit Margin: 6496 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6496 is unprofitable, and losses have increased over the past 5 years at a rate of 75.4% per year.
Accelerating Growth: Unable to compare 6496's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6496 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (5.9%).
Return on Equity
High ROE: 6496 has a negative Return on Equity (-8.19%), as it is currently unprofitable.